カテゴリー： 世界, 医療/バイオ, GlobalInfoResearch

世界のアダリムマブ（ヒュミラ）&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析

【英語タイトル】Global Adalimumab (Humira) and Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

GlobalInfoResearchが出版した調査資料（GIR23SM7762）・商品コード：GIR23SM7762
・発行会社（調査会社）：GlobalInfoResearch
・発行日：2023年9月
・ページ数：100
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（注文後2-3日）
・調査対象地域：グローバル
・産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

GlobalInfoResearchの最新の調査によると、世界のアダリムマブ（ヒュミラ）&バイオシミラーの市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界のアダリムマブ（ヒュミラ）&バイオシミラー市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、タイプ別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- アダリムマブ（ヒュミラ）&バイオシミラーの成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

アダリムマブ（ヒュミラ）&バイオシミラー市場はタイプと用途によって区分されます。2018年～2029年において、量と金額の観点からタイプ別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメント
・シリンジ、ペン

用途別セグメント
・強直性脊椎炎、関節リウマチ、クローン病、その他

主要な市場プレーヤー
・AbbVie、Eisai、Cadila Healthcare、Torrent Pharmaceuticals、Amgen、Boehringer Ingelheim、Novartis、Samsung Bioepis、Viatris、Pfizer、Fresenius Kabi、Coherus

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、アダリムマブ（ヒュミラ）&バイオシミラー製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なアダリムマブ（ヒュミラ）&バイオシミラーメーカーの企業概要、2019年～2022年までのアダリムマブ（ヒュミラ）&バイオシミラーの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なアダリムマブ（ヒュミラ）&バイオシミラーメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別アダリムマブ（ヒュミラ）&バイオシミラーの販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までのアダリムマブ（ヒュミラ）&バイオシミラーのタイプ別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのアダリムマブ（ヒュミラ）&バイオシミラー市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、およびアダリムマブ（ヒュミラ）&バイオシミラーの産業チェーンを掲載しています。
・第14、15章では、アダリムマブ（ヒュミラ）&バイオシミラーの販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– アダリムマブ（ヒュミラ）&バイオシミラーの概要
– タイプ別分析（2018年vs2022年vs2029年）：シリンジ、ペン
– 用途別分析（2018年vs2022年vs2029年）：強直性脊椎炎、関節リウマチ、クローン病、その他
– 世界のアダリムマブ（ヒュミラ）&バイオシミラー市場規模・予測
– 世界のアダリムマブ（ヒュミラ）&バイオシミラー生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– AbbVie、Eisai、Cadila Healthcare、Torrent Pharmaceuticals、Amgen、Boehringer Ingelheim、Novartis、Samsung Bioepis、Viatris、Pfizer、Fresenius Kabi、Coherus
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・タイプ別分析2018年-2029年：シリンジ、ペン
・用途別分析2018年-2029年：強直性脊椎炎、関節リウマチ、クローン病、その他
・アダリムマブ（ヒュミラ）&バイオシミラーの北米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・アダリムマブ（ヒュミラ）&バイオシミラーのヨーロッパ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・アダリムマブ（ヒュミラ）&バイオシミラーのアジア市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・アダリムマブ（ヒュミラ）&バイオシミラーの南米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・アダリムマブ（ヒュミラ）&バイオシミラーの中東・アフリカ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Market Overview
1.1 Product Overview and Scope of Adalimumab (Humira) and Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Adalimumab (Humira) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Syringe
1.3.3 Pen
1.4 Market Analysis by Application
1.4.1 Overview: Global Adalimumab (Humira) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Ankylosing Spondylitis
1.4.3 Rheumatoid Arthritis
1.4.4 Crohn’s Disease
1.4.5 Other
1.5 Global Adalimumab (Humira) and Biosimilar Market Size & Forecast
1.5.1 Global Adalimumab (Humira) and Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Adalimumab (Humira) and Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Adalimumab (Humira) and Biosimilar Average Price (2018-2029)
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Adalimumab (Humira) and Biosimilar Product and Services
2.1.4 AbbVie Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AbbVie Recent Developments/Updates
2.2 Eisai
2.2.1 Eisai Details
2.2.2 Eisai Major Business
2.2.3 Eisai Adalimumab (Humira) and Biosimilar Product and Services
2.2.4 Eisai Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Eisai Recent Developments/Updates
2.3 Cadila Healthcare
2.3.1 Cadila Healthcare Details
2.3.2 Cadila Healthcare Major Business
2.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
2.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Cadila Healthcare Recent Developments/Updates
2.4 Torrent Pharmaceuticals
2.4.1 Torrent Pharmaceuticals Details
2.4.2 Torrent Pharmaceuticals Major Business
2.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
2.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Torrent Pharmaceuticals Recent Developments/Updates
2.5 Amgen
2.5.1 Amgen Details
2.5.2 Amgen Major Business
2.5.3 Amgen Adalimumab (Humira) and Biosimilar Product and Services
2.5.4 Amgen Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Amgen Recent Developments/Updates
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
2.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Boehringer Ingelheim Recent Developments/Updates
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Adalimumab (Humira) and Biosimilar Product and Services
2.7.4 Novartis Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis Recent Developments/Updates
2.8 Samsung Bioepis
2.8.1 Samsung Bioepis Details
2.8.2 Samsung Bioepis Major Business
2.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
2.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Samsung Bioepis Recent Developments/Updates
2.9 Viatris
2.9.1 Viatris Details
2.9.2 Viatris Major Business
2.9.3 Viatris Adalimumab (Humira) and Biosimilar Product and Services
2.9.4 Viatris Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Viatris Recent Developments/Updates
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Adalimumab (Humira) and Biosimilar Product and Services
2.10.4 Pfizer Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Pfizer Recent Developments/Updates
2.11 Fresenius Kabi
2.11.1 Fresenius Kabi Details
2.11.2 Fresenius Kabi Major Business
2.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
2.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Fresenius Kabi Recent Developments/Updates
2.12 Coherus
2.12.1 Coherus Details
2.12.2 Coherus Major Business
2.12.3 Coherus Adalimumab (Humira) and Biosimilar Product and Services
2.12.4 Coherus Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Coherus Recent Developments/Updates
3 Competitive Environment: Adalimumab (Humira) and Biosimilar by Manufacturer
3.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Adalimumab (Humira) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Adalimumab (Humira) and Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Adalimumab (Humira) and Biosimilar Manufacturer Market Share in 2022
3.5 Adalimumab (Humira) and Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Adalimumab (Humira) and Biosimilar Market: Region Footprint
3.5.2 Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
3.5.3 Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Adalimumab (Humira) and Biosimilar Market Size by Region
4.1.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2029)
4.2 North America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.3 Europe Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.5 South America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029)
7 North America
7.1 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Adalimumab (Humira) and Biosimilar Market Size by Country
7.3.1 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Adalimumab (Humira) and Biosimilar Market Size by Country
8.3.1 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Adalimumab (Humira) and Biosimilar Market Size by Region
9.3.1 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Adalimumab (Humira) and Biosimilar Market Size by Country
10.3.1 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Adalimumab (Humira) and Biosimilar Market Size by Country
11.3.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Adalimumab (Humira) and Biosimilar Market Drivers
12.2 Adalimumab (Humira) and Biosimilar Market Restraints
12.3 Adalimumab (Humira) and Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Adalimumab (Humira) and Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Adalimumab (Humira) and Biosimilar
13.3 Adalimumab (Humira) and Biosimilar Production Process
13.4 Adalimumab (Humira) and Biosimilar Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Adalimumab (Humira) and Biosimilar Typical Distributors
14.3 Adalimumab (Humira) and Biosimilar Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. AbbVie Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Major Business
Table 5. AbbVie Adalimumab (Humira) and Biosimilar Product and Services
Table 6. AbbVie Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. AbbVie Recent Developments/Updates
Table 8. Eisai Basic Information, Manufacturing Base and Competitors
Table 9. Eisai Major Business
Table 10. Eisai Adalimumab (Humira) and Biosimilar Product and Services
Table 11. Eisai Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Eisai Recent Developments/Updates
Table 13. Cadila Healthcare Basic Information, Manufacturing Base and Competitors
Table 14. Cadila Healthcare Major Business
Table 15. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
Table 16. Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Cadila Healthcare Recent Developments/Updates
Table 18. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Torrent Pharmaceuticals Major Business
Table 20. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
Table 21. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Torrent Pharmaceuticals Recent Developments/Updates
Table 23. Amgen Basic Information, Manufacturing Base and Competitors
Table 24. Amgen Major Business
Table 25. Amgen Adalimumab (Humira) and Biosimilar Product and Services
Table 26. Amgen Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Amgen Recent Developments/Updates
Table 28. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 29. Boehringer Ingelheim Major Business
Table 30. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
Table 31. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Boehringer Ingelheim Recent Developments/Updates
Table 33. Novartis Basic Information, Manufacturing Base and Competitors
Table 34. Novartis Major Business
Table 35. Novartis Adalimumab (Humira) and Biosimilar Product and Services
Table 36. Novartis Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Novartis Recent Developments/Updates
Table 38. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 39. Samsung Bioepis Major Business
Table 40. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
Table 41. Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Samsung Bioepis Recent Developments/Updates
Table 43. Viatris Basic Information, Manufacturing Base and Competitors
Table 44. Viatris Major Business
Table 45. Viatris Adalimumab (Humira) and Biosimilar Product and Services
Table 46. Viatris Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Viatris Recent Developments/Updates
Table 48. Pfizer Basic Information, Manufacturing Base and Competitors
Table 49. Pfizer Major Business
Table 50. Pfizer Adalimumab (Humira) and Biosimilar Product and Services
Table 51. Pfizer Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Pfizer Recent Developments/Updates
Table 53. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 54. Fresenius Kabi Major Business
Table 55. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
Table 56. Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Fresenius Kabi Recent Developments/Updates
Table 58. Coherus Basic Information, Manufacturing Base and Competitors
Table 59. Coherus Major Business
Table 60. Coherus Adalimumab (Humira) and Biosimilar Product and Services
Table 61. Coherus Adalimumab (Humira) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Coherus Recent Developments/Updates
Table 63. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 64. Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)
Table 65. Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 66. Market Position of Manufacturers in Adalimumab (Humira) and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 67. Head Office and Adalimumab (Humira) and Biosimilar Production Site of Key Manufacturer
Table 68. Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
Table 69. Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
Table 70. Adalimumab (Humira) and Biosimilar New Market Entrants and Barriers to Market Entry
Table 71. Adalimumab (Humira) and Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 72. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 73. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 74. Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 75. Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 76. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 77. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 78. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2018-2023) & (USD Million)
Table 81. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2024-2029) & (USD Million)
Table 82. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 83. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 84. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 85. Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 86. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2018-2023) & (USD Million)
Table 87. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2024-2029) & (USD Million)
Table 88. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 89. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 90. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 91. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 92. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 93. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 94. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 95. North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 96. North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 97. North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 99. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 100. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 101. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 102. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 103. Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 104. Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 107. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 108. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 109. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 110. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 111. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 112. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 113. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 114. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 115. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 116. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 117. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 118. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 119. South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 120. South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 121. South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 122. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 123. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 124. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 125. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 126. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 127. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 128. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 129. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 130. Adalimumab (Humira) and Biosimilar Raw Material
Table 131. Key Manufacturers of Adalimumab (Humira) and Biosimilar Raw Materials
Table 132. Adalimumab (Humira) and Biosimilar Typical Distributors
Table 133. Adalimumab (Humira) and Biosimilar Typical Customers
List of Figures
Figure 1. Adalimumab (Humira) and Biosimilar Picture
Figure 2. Global Adalimumab (Humira) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Type in 2022
Figure 4. Syringe Examples
Figure 5. Pen Examples
Figure 6. Global Adalimumab (Humira) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Application in 2022
Figure 8. Ankylosing Spondylitis Examples
Figure 9. Rheumatoid Arthritis Examples
Figure 10. Crohn’s Disease Examples
Figure 11. Other Examples
Figure 12. Global Adalimumab (Humira) and Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Adalimumab (Humira) and Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Adalimumab (Humira) and Biosimilar Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Adalimumab (Humira) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Adalimumab (Humira) and Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Adalimumab (Humira) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Adalimumab (Humira) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 54. China Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Adalimumab (Humira) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Adalimumab (Humira) and Biosimilar Market Drivers
Figure 75. Adalimumab (Humira) and Biosimilar Market Restraints
Figure 76. Adalimumab (Humira) and Biosimilar Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Adalimumab (Humira) and Biosimilar in 2022
Figure 79. Manufacturing Process Analysis of Adalimumab (Humira) and Biosimilar
Figure 80. Adalimumab (Humira) and Biosimilar Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source


★調査レポート[世界のアダリムマブ（ヒュミラ）&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析] (コード：GIR23SM7762)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のアダリムマブ（ヒュミラ）&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のレミケード（インフリキシマブ）&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析
  • 世界のエンブレル（エタネルセプト）&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析
  • 世界のハーセプチン（トラスツズマブ）&バイオシミラー市場2023年：企業・地域・タイプ・用途別分析
  • 世界のヒュミラバイオシミラー市場2023年：企業・地域・タイプ・用途別分析
  • 世界のアダリムマブ注射液市場2023年：企業・地域・タイプ・用途別分析
  • 世界のレテルモビル注射市場2023年：企業・地域・タイプ・用途別分析
  • 世界の単回使用胃カメラ市場2023年：企業・地域・タイプ・用途別分析
  • 世界のボスチニブ一水和物錠市場2023年：企業・地域・タイプ・用途別分析
  • 世界のピーナッツプロテインパッチ市場2023年：企業・地域・タイプ・用途別分析
  • 世界のスプレー凍結療法装置市場2023年：企業・地域・タイプ・用途別分析

    • ◆H&Iグローバルリサーチのお客様（例）◆